Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2006 Sep;6(9):935-42.

Role of abciximab in the treatment of coronary artery disease.

Author information

  • 1Unidade de Cardiologia de Intervenção Joaquim Oliveira, Serviço de Cardiologia, Hospital de Santa Maria, Avenida Egas Moniz, 1649-035 Lisboa, Portugal. hmgabriel@netcabo.pt

Abstract

Glycoprotein IIb/IIIa complex is a crucial membrane receptor for platelet aggregation, binding platelets to fibrinogen and establishing interplatelet bridges. This receptor is the common end point of the multiple activation pathways of a platelet. Antiplatelet agents, such as aspirin or thienopyridines, including ticlopidine and clopidogrel, inhibit one or more but not all, of these pathways. Inhibitors of the receptor are powerful platelet antiaggregants and include two groups of agents: non-competitive receptor blockers, such as abciximab, and competitive antagonists, such as tirofiban and eptifibatide. Abciximab is a monoclonal antibody that binds to the glycoprotein IIb/IIIa complex, thus blocking the interaction with fibrinogen. It is used for treatment of coronary artery disease, being well-studied in the setting of acute coronary syndromes and percutaneous coronary intervention, in which a rapid and effective antiaggregation is clinically important.

PMID:
16918260
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk